Illumina Inc, a global leader in DNA sequencing and array-based technologies, is supporting the advancement of genomics and multi-omics research and clinical adoption in India - contributing to the growth of precision medicine and biomedical innovation, and helping advance the future of healthcare.
To this end, the Illumina Multiomics Summit India 2026 brought together over 200 genomics experts, clinicians, pathologists, translational researchers, and scientists. The two-city event, hosted in New Delhi (May 6) and Bengaluru (May 8) in collaboration with Premas Life Sciences, explored the transformative potential of multi-omics in advancing life sciences and precision health.
The summit highlighted the shift from single-omics studies to integrated multi-omics to accelerate discovery and enable more precise, data-driven healthcare. By combining layers of biological data - including genomics, transcriptomics, epigenomics and proteomics -researchers can build a more complete view of disease biology to support translational research and future clinical applications.
This shift is particularly important for India’s highly diverse population and growing healthcare needs. With nearly 1.4 billion people and extensive genetic, cultural, and linguistic diversity, the country provides a strong foundation for large-scale biomedical research and discovery. At the same time, India faces a significant burden of disease, including an estimated 77 million people living with diabetes and a substantial proportion of deaths attributable to cardiovascular disease. It is further estimated that up to 96 million people in India may be affected by rare diseases, and that one in nine individuals is likely to develop cancer in their lifetime - underscoring the need for more predictive and personalised approaches to healthcare.
“Multi-omics is reshaping our understanding of biology by moving from isolated data layers to a more integrated view of disease - an approach that is increasingly becoming important for advancing precision health and is beginning to inform clinical space, particularly in oncology,” said Suchita Dayanand, Country Head – India (Commercial) at Illumina.
“As Illumina grows in India, we work closely with our customers to understand their needs, opportunities, and how we can continue to support them. As genomics becomes part of standard care in many cancers, integrated omics approaches have the potential to enable research insights for more precise diagnosis and treatment decisions. Through industry collaboration, initiatives such as the Illumina Multiomics Summit, and ongoing innovation including TruPathTM, we aim to simplify sequencing and support deeper genomic insights - helping advance the profiling of cancer and rare diseases,” she added.
Backed by one of the world’s significant pools of bioinformatics and life sciences talent, India’s biotechnology sector is projected to reach $150–$300 billion by 2030, while the country remains a significant contributor to global clinical research activity.
